Rigel Pharmaceuticals (RIGL) grants director 12,000 stock options at $34.86

Rhea-AI Filing Summary

Rigel Pharmaceuticals director receives new stock option grant. Director Michael Patrick Miller was awarded a stock option for 12,000 shares of Rigel common stock on February 1, 2026, with an exercise price of $34.86 per share. The option vests in equal monthly installments from February 1, 2026 until the annual meeting at which he is first scheduled to be considered for election by stockholders, conditioned on his continued service on the board.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

MILLER MICHAEL PATRICK

(Last) (First) (Middle)

RIGEL PHARMACEUTICALS, INC.

611 GATEWAY BLVD, SUITE 900

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
RIGEL PHARMACEUTICALS INC [ RIGL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/01/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$34.86	02/01/2026		A		12,000		(1)	02/01/2036	Common Stock	12,000	$0	12,000	D

Explanation of Responses:

1. The option shall vest in equal monthly installments over a period beginning on February 1, 2026 and ending on the date of the annual meeting at which the Reporting Person is first scheduled to be considered for election by the stockholders, subject to the Reporting Person's continuous service on the Company's Board of Directors.

	/s/ Raymond Furey (Attorney-in-Fact)	02/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Rigel Pharmaceuticals (RIGL) disclose for Michael Patrick Miller?

Rigel Pharmaceuticals reported that director Michael Patrick Miller received a stock option grant for 12,000 shares of common stock on February 1, 2026, with an exercise price of $34.86 per share. This is a derivative security giving him the right to buy shares in the future.

What are the key terms of Michael Patrick Miller’s Rigel (RIGL) stock option?

Michael Patrick Miller’s stock option covers 12,000 shares of Rigel common stock at a $34.86 exercise price. The option was granted on February 1, 2026 and is held directly, with 12,000 derivative securities beneficially owned following the reported transaction.

How does Michael Patrick Miller’s Rigel (RIGL) option award vest?

The option vests in equal monthly installments beginning February 1, 2026 and ending on the date of the annual meeting when he is first scheduled to be considered for election by stockholders. Vesting is contingent on his continuous service on Rigel’s Board of Directors.

What is the expiration date of the Rigel (RIGL) stock option granted to Michael Patrick Miller?

The stock option granted to Michael Patrick Miller expires on February 1, 2036. Until that expiration date, he may exercise the option to purchase up to 12,000 shares of Rigel common stock at the fixed exercise price of $34.86 per share.

Is Michael Patrick Miller’s Rigel (RIGL) stock option held directly or indirectly?

The Form 4 indicates Michael Patrick Miller holds the 12,000 stock options directly. The ownership form is marked as “D” for direct, and no nature of indirect beneficial ownership is listed, meaning the award is reported as personally held rather than through another entity.